OncoCyte changes name to Insight Molecular Diagnostics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2025
0mins
Should l Buy ?
Company Name Change and Relocation: Insight Molecular Diagnostics has renamed itself to iMDx and relocated its principal executive office from Irvine, California to Nashville, Tennessee, with a new stock symbol "IMDX" starting June 18, 2025. This change reflects the company's expanded focus on transplant medicine alongside oncology.
Product Branding and Development: The company is unifying its transplant diagnostics under the GraftAssure brand, which includes GraftAssureCore, GraftAssureIQ, and GraftAssureDx, aligning product names with regulatory classifications while aiming to enhance testing access for kidney transplant patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
